2Seventy Bio Inc TSVT:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 05/21/24 EDT
4.38UNCH (UNCH)
Volume
371,854
52 week range
1.53 - 12.69
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close4.38
  • 52 Week High12.69
  • 52 Week High Date06/09/23
  • 52 Week Low1.53
  • 52 Week Low Date11/22/23

Key Stats

  • Market Cap225.156M
  • Shares Out51.41M
  • 10 Day Average Volume0.41M
  • Dividend-
  • Dividend Yield-
  • Beta1.87
  • YTD % Change2.58

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close4.38
  • 52 Week High12.69
  • 52 Week High Date06/09/23
  • 52 Week Low1.53
  • 52 Week Low Date11/22/23
  • Market Cap225.156M
  • Shares Out51.41M
  • 10 Day Average Volume0.41M
  • Dividend-
  • Dividend Yield-
  • Beta1.87
  • YTD % Change2.58

RATIOS/PROFITABILITY

  • EPS (TTM)-4.34
  • P/E (TTM)-1.01
  • Fwd P/E (NTM)-1.84
  • EBITDA (TTM)-200.782M
  • ROE (TTM)-73.34%
  • Revenue (TTM)71.201M
  • Gross Margin (TTM)77.68%
  • Net Margin (TTM)-313.51%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/12/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On 2Seventy Bio Inc

 

Profile

MORE
2seventy bio, Inc. is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The Company is focused on the commercialization and development of Abecma (idecabtagene vicleucel). Abecma is its B cell maturation antigen (BCMA)-targeted CAR T cell therapy for multiple myeloma, in collaboration with their partner Bristol Myers Squibb (BMS). ABECMA is a BCMA-directed genetically modified autologous T cell...
Daniel Lynch
Independent Chairman of the Board
Nick Leschly
President, Chief Executive Officer, Director
William Baird III
Chief Financial Officer, Chief Operating Officer
Address
60 Binney Street
Cambridge, MA
02210
United States

Top Peers

SYMBOLLASTCHG%CHG
ENTA
Enanta Pharmaceuticals Inc
12.47UNCHUNCH
GTHX
G1 Therapeutics Inc
4.53-0.02-0.44%
PSTX
Poseida Therapeutics Inc
2.97-0.19-6.01%
RCEL
AVITA Medical Inc
8.14-0.03-0.37%
ADCT
ADC Therapeutics SA
3.73-0.38-9.25%